...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The FEBS journal >Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins
【24h】

Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins

机译：Lumican在控制肿瘤进展中的作用及其与金属蛋白酶和整联蛋白的联系

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lumican is a member of the small leucine-rich proteoglycan family. It is present in numerous extracellular matrices of different tissues, such as muscle, cartilage, and cornea. In skin, lumican is present as a glycoprotein. It plays a critical role incollagen fibrillogenesis, as shown by knocking out of its gene in mice. A direct link between lumican expression and melanoma progression and metastasis has been demonstrated. Lumican was shown to impede tumour cell migration and invasion by directly interacting with the alpha_2 beta_1 integrin. In addition, an active sequence of the lumican core protein, called lumcorin, was identified as being responsible for inhibition of melanoma cell migration. Lumican was also shown to exert angiostatic properties by downregulating the proteolytic activity associated with endothelial cell membranes, particularly matrix metalloproteinase (MMP)-14 and MMP-9. Globally, lumican appears to be a potent agent for inhibiting tumour progression rather than tumorigenesis.However, progressive changes in proteoglycans occur in the tumour environment. The complexity and diversity of proteoglycan structure might be responsible for a variety of functions that regulate cell behaviour. Through their core protein and their glycosaminoglycan chains, proteoglycans can interact with growth factors and chemokines. These interactions affect cell signalling, motility, adhesion, growth, and apoptosis. This review summarizes recent data concerning lumican control of tumour progressionin different cancers, with a particular focus on its interactions with MMPs and integrins. Its potential therapeutic implications are discussed.
机译：Lumican是富含亮氨酸的小蛋白聚糖家族的成员。它存在于许多不同组织的细胞外基质中，例如肌肉，软骨和角膜。在皮肤中，卢米肯以糖蛋白形式存在。如在小鼠中敲除其基因所示，它在胶原原纤维形成中起关键作用。 Lumican表达与黑色素瘤进展和转移之间存在直接联系。 Lumican已显示通过直接与alpha_2 beta_1整合素相互作用来阻止肿瘤细胞迁移和侵袭。此外，还确认了称为卢科林（lumcorin）的Lumican核心蛋白的活性序列可抑制黑色素瘤细胞的迁移。 Lumican还显示出通过下调与内皮细胞膜有关的蛋白水解活性（特别是基质金属蛋白酶（MMP）-14和MMP-9）发挥血管抑制作用。在全球范围内，卢米聚糖似乎是抑制肿瘤进展而不是肿瘤发生的有效药物，但是，在肿瘤环境中蛋白聚糖逐渐发生变化。蛋白聚糖结构的复杂性和多样性可能是调节细胞行为的多种功能的原因。通过其核心蛋白和其糖胺聚糖链，蛋白聚糖可以与生长因子和趋化因子相互作用。这些相互作用影响细胞信号传导，运动性，粘附，生长和凋亡。这篇综述总结了有关Lumican控制不同癌症中肿瘤进展的最新数据，特别关注它与MMP和整联蛋白的相互作用。讨论了其潜在的治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号